<DOC>
	<DOCNO>NCT02602028</DOCNO>
	<brief_summary>It aim examine efficacy safety daily dosage schema colchicine pediatric patient FMF compare twice daily dosage schema . In 24-week , multicentric , randomize , control , noninferiority trial , pediatric patient newly diagnose FMF , carry homozygote compound heterozygote mutation receive treatment , include . Patients randomly assign use block randomization method receive treatment twice daily dos . Clinical laboratory characteristic medication side effect record compare group . The study comply Good Clinical Practice Consolidated Standards Reporting Trials ( CONSORT ) statement .</brief_summary>
	<brief_title>The Comparison Efficacy Once Twice Daily Colchicine Dosage Pediatric Patients With FMF</brief_title>
	<detailed_description>Study design This study conduct member FMF Arthritis Vasculitis Orphan disease Research Pediatric Rheumatology ( FAVOR , www.favor.org.tr ) 10 center Turkey . This multicentric randomized control , noninferiority trial two parallel group follow pediatric rheumatology outpatient clinic . The randomization do baseline visit patient assess two visit , three month apart . The study comply Good Clinical Practice ( GCP ) Consolidated Standards Reporting Trials ( CONSORT ) statement . Participants Inclusion criterion Pediatric patient newly diagnose Familial Mediterranean Fever accord Yalcinkaya Tel-Hashomer criterion confirm genetic analysis compound heterozygote homozygote mutation enrol . Eligible patient age 5-16 weighted 15-30 kg receive treatment include . All patient include asked physician prove record least one FMF attack enrollment study . Exclusion criteria Patients major congenital malformation , risk pregnancy , chronic disease organ transplantation , hepatic disorder chronic kidney disease AA amyloidosis , thyroid disease rheumatologic disorder FMF , exclude . Baseline assessment Outcome Measures At baseline visit , medical history complaint disease question physical examination laboratory test perform . In follow visit , attack finding due colchicine since last visit investigate addition baseline visit . Interventions The daily dosage group prescribe daily 08:00 a.m. twice daily dosage group receive treatment twice daily 08:00 a.m. 08:00 p.m. Disease severity assess via Mor score system , modify pediatric patient visit . A physician center choose responsible data collection . After visit data register web-based registry system `` www.favor.org.tr '' web site . To ensure accurate , complete , reliable data , follow procedure follow : data collection , encode , storage provide center ; train session hold provide instruction protocol ; periodic meeting hold study coordinator principal investigator stay contact study coordinator mail , telephone , and/or fax ; finally data manager review evaluate data . Colchicine dosage The required colchicine dosage calculate total 1 mg daily accord internationally accepted advisory . All patient prescribe 0.5 mg Colchicine tablet . Patients daily dosage group give 2 tablet Colchicine 08.00 a.m. Twice daily dosage group receive 1 tablet 0,5 mg Colchicine 08:00 a.m. 1 tablet 0,5 mg Colchicine 08:00 p.m .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Brucellosis</mesh_term>
	<mesh_term>Familial Mediterranean Fever</mesh_term>
	<mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Diagnosed Familial Mediterranean Fever accord Yalcinkaya TelHashomer criterion Diagnosis confirm genetic analysis compound heterozygote homozygote mutation Patients age 516 weighted 1530 kg Not receive treatment FMF Exclusion criterion : Major congenital malformation Organ transplantation Hepatic disorder Chronic kidney disease AA amyloidosis Thyroid disease Rheumatologic disorder FMF</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Familial Mediterranean Fever</keyword>
	<keyword>Colchicine</keyword>
</DOC>